Heather A. Boger
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Heather A. Boger has a total of 41 co-authors. Here are the top co-authors by number of shared publications:
- Ariana Q. Farrand
Department of Biomedical Sciences Quillen College of Medicine East Tennessee State University Johnson City TN USA
4 shared publications Rebecca A. Gregory
Dept of Comparative Medicine, Medical University of South Carolina, 114 Doughty St, STB 648, MSC 777, Charleston, SC, 29425, USA
4 shared publicationsAnn-Charlotte Granholm
Department of Neurosciences and Center on Aging, Medical University of South Carolina, 173 Ashley Ave., BSB Suite 403, Charleston, SC 29425, USA
3 shared publications- Kristi L. Helke
Department of Comparative Medicine, Medical University of South Carolina, Charleston, SC, USA
3 shared publications Vanessa K. Hinson
Department of Neurology, Medical University of South Carolina, 96 Jonathan Lucas St, CSB 309, MSC 606, Charleston, SC, 29425, USA
3 shared publicationsGreg A. Gerhardt
Department of Anatomy and Neurobiology, Parkinson’s Disease Translational Research Center of Excellence, University of Kentucky Medical Center, 306 Davis Mills Bldg., 800 Rose St., Lexington, KY 40536, USA
2 shared publications
Latest Publications
- Open Access
- 22 August 2023
- Published by Elsevier in Brain Stimulation
- Vol. 16 (5) , 1240-1242
Transcutaneous auricular vagus nerve stimulation (taVNS) decreases heart rate acutely in neonatal rats
- 22 August 2023
- Published by Elsevier in Brain Stimulation
- Vol. 16 (5) , 1240-1242
Open AccessTranscutaneous auricular vagus nerve stimulation (taVNS) decreases heart rate acutely in neonatal rats
- Open Access
- 1 September 2020
- Published by Elsevier in Brain Stimulation
- Vol. 13 (5) , 1323-1332
Differential effects of vagus nerve stimulation paradigms guide clinical development for Parkinson’s disease
- 1 September 2020
- Published by Elsevier in Brain Stimulation
- Vol. 13 (5) , 1323-1332
Open AccessDifferential effects of vagus nerve stimulation paradigms guide clinical development for Parkinson’s disease
- 1 November 2019
- Published by Elsevier in Behavioural Brain Research
- Vol. 373, 112080
Effects of vagus nerve stimulation are mediated in part by TrkB in a parkinson’s disease model
- 1 November 2019
- Published by Elsevier in Behavioural Brain Research
- Vol. 373, 112080
Effects of vagus nerve stimulation are mediated in part by TrkB in a parkinson’s disease model
- 22 December 2017
- Published by Wiley in British Journal of Pharmacology
- Vol. 175 (2) , 348-358
5‐HT1F receptor‐mediated mitochondrial biogenesis for the treatment of Parkinson's disease
Background and Purpose: Parkinson's disease is characterized by progressive decline in motor function due to degeneration of nigrostriatal dopaminergic neurons, as well as other deficits including cognitive impairment and behavioural abnormalities. Mitochondrial dysfunction, leading to loss of ATP‐dependent cellular functions, calcium overload, excitotoxicity and oxidative stress, is implicated in the pathophysiology of Parkinson's disease. Using the 5‐HT1F receptor agonist LY344864, a known inducer of mitochondrial biogenesis (MB), we investigated the therapeutic efficacy of stimulating MB on dopaminergic neuron loss in a mouse model of Parkinson's disease.Experimental Approach: Male C57BL/6 mice underwent bilateral intrastriatal 6‐hydroxydopamine or saline injections and daily treatment with 2 mg·kg−1 LY344864 or vehicle for 14 days beginning 7 days post‐lesion. Tyrosine hydroxylase immunoreactivity (TH‐ir) and MB were assessed in the brains of all groups following treatment, and locomotor activity was evaluated prior to lesioning, 7 days post‐lesion and after treatment.Key Results: Increased mitochondrial DNA content and nuclear‐ and mitochondrial‐encoded mRNA and protein expression was observed in specific brain regions of LY344864‐treated naïve and lesioned mice, indicating augmented MB. LY344864 attenuated TH‐ir loss in the striatum and substantia nigra compared to vehicle‐treated lesioned animals. LY344864 treatment also increased locomotor activity in 6‐hydroxydopamine lesioned mice, while vehicle treatment had no effect.Conclusions and Implications: These data revealed that LY344864‐induced MB attenuates dopaminergic neuron loss and improves behavioural endpoints in this model. We suggest that stimulating MB may be beneficial for the treatment of Parkinson's disease and that the 5‐HT1F receptor may be an effective therapeutic target.
- 22 December 2017
- Published by Wiley in British Journal of Pharmacology
- Vol. 175 (2) , 348-358
5‐HT1F receptor‐mediated mitochondrial biogenesis for the treatment of Parkinson's disease
Background and Purpose: Parkinson's disease is characterized by progressive decline in motor function due to degeneration of nigrostriatal dopaminergic neurons, as well as other deficits including cognitive impairment and behavioural abnormalities. Mitochondrial dysfunction, leading to loss of ATP‐dependent cellular functions, calcium overload, excitotoxicity and oxidative stress, is implicated in the pathophysiology of Parkinson's disease. Using the 5‐HT1F receptor agonist LY344864, a known inducer of mitochondrial biogenesis (MB), we investigated the therapeutic efficacy of stimulating MB on dopaminergic neuron loss in a mouse model of Parkinson's disease.Experimental Approach: Male C57BL/6 mice underwent bilateral intrastriatal 6‐hydroxydopamine or saline injections and daily treatment with 2 mg·kg−1 LY344864 or vehicle for 14 days beginning 7 days post‐lesion. Tyrosine hydroxylase immunoreactivity (TH‐ir) and MB were assessed in the brains of all groups following treatment, and locomotor activity was evaluated prior to lesioning, 7 days post‐lesion and after treatment.Key Results: Increased mitochondrial DNA content and nuclear‐ and mitochondrial‐encoded mRNA and protein expression was observed in specific brain regions of LY344864‐treated naïve and lesioned mice, indicating augmented MB. LY344864 attenuated TH‐ir loss in the striatum and substantia nigra compared to vehicle‐treated lesioned animals. LY344864 treatment also increased locomotor activity in 6‐hydroxydopamine lesioned mice, while vehicle treatment had no effect.Conclusions and Implications: These data revealed that LY344864‐induced MB attenuates dopaminergic neuron loss and improves behavioural endpoints in this model. We suggest that stimulating MB may be beneficial for the treatment of Parkinson's disease and that the 5‐HT1F receptor may be an effective therapeutic target.
- 1 November 2017
- Published by Elsevier in Brain Stimulation
- Vol. 10 (6) , 1045-1054
Vagus nerve stimulation improves locomotion and neuronal populations in a model of Parkinson's disease
- 1 November 2017
- Published by Elsevier in Brain Stimulation
- Vol. 10 (6) , 1045-1054
Vagus nerve stimulation improves locomotion and neuronal populations in a model of Parkinson's disease
- 1 November 2016
- Published by Elsevier in Brain Research
- Vol. 1651, 88-94
Altered glutamate release in the dorsal striatum of the MitoPark mouse model of Parkinson's disease
- 1 November 2016
- Published by Elsevier in Brain Research
- Vol. 1651, 88-94
Altered glutamate release in the dorsal striatum of the MitoPark mouse model of Parkinson's disease
- 1 March 2015
- Published by Elsevier in Neurobiology of Aging
- Vol. 36 (3) , 1569-1576
Effects of aging on glutamate neurotransmission in the substantia nigra of Gdnf heterozygous mice
- 1 March 2015
- Published by Elsevier in Neurobiology of Aging
- Vol. 36 (3) , 1569-1576
Effects of aging on glutamate neurotransmission in the substantia nigra of Gdnf heterozygous mice
- Open Access
- 16 December 2014
- Published by Springer Nature in Journal of Neuroinflammation
- Vol. 11 (1) , 171
Estrogen receptor alpha deficiency protects against development of cognitive impairment in murine lupus
One of the more profound features of systemic lupus erythematosus (SLE) is that females have a 9:1 prevalence of this disease over males. Up to 80% of SLE patients have cognitive defects or affective disorders. The mechanism of CNS injury responsible for cognitive impairment is unknown. We previously showed that ERα deficiency significantly reduced renal disease and increased survival in lupus-prone mice. We hypothesized that ERα deficiency would be similarly protective in the brain, and that ERα may play a role in modulating blood-brain barrier (BBB) integrity and/or neuroinflammation in lupus-prone mice. MRL/lpr ERα+/+ and ERαKO mice (n = 46) were ovariectomized, received 17β-estradiol pellets, and underwent radial arm water maze (WRAM) and novel object recognition (NOR) testing starting at eight weeks of age. Mice were sacrificed and brains were hemisected and processed for either immunohistochemistry, or hippocampus and parietal cortex dissection for Western blotting. MRL/lpr ERαKO mice (n = 21) performed significantly better in WRAM testing than wild-type MRL/lpr mice (n = 25). There was a significant reduction in reference memory errors (P <0.007), working memory errors (P <0.05), and start arm errors (P <0.02) in ERαKO mice. There were significant differences in NOR testing, particularly total exploration time, with ERα deficiency normalizing behavior. No significant differences were seen in markers of tight junction, astrogliosis, or microgliosis in the hippocampus or cortex by Western blot, however, there was a significant reduction in numbers of Iba1+ activated microglia in the hippocampus of ERαKO mice, as evidenced by immunohistochemietry (IHC). ERα deficiency provides significant protection against cognitive deficits in MRL/lpr mice as early as eight weeks of age. Additionally, the significant reduction in Iba1+ activated microglia in the MRL/lpr ERαKO mice was consistent with reduced inflammation, and may represent a biological mechanism for the cognitive improvement observed.
- 16 December 2014
- Published by Springer Nature in Journal of Neuroinflammation
- Vol. 11 (1) , 171
Open AccessEstrogen receptor alpha deficiency protects against development of cognitive impairment in murine lupus
One of the more profound features of systemic lupus erythematosus (SLE) is that females have a 9:1 prevalence of this disease over males. Up to 80% of SLE patients have cognitive defects or affective disorders. The mechanism of CNS injury responsible for cognitive impairment is unknown. We previously showed that ERα deficiency significantly reduced renal disease and increased survival in lupus-prone mice. We hypothesized that ERα deficiency would be similarly protective in the brain, and that ERα may play a role in modulating blood-brain barrier (BBB) integrity and/or neuroinflammation in lupus-prone mice. MRL/lpr ERα+/+ and ERαKO mice (n = 46) were ovariectomized, received 17β-estradiol pellets, and underwent radial arm water maze (WRAM) and novel object recognition (NOR) testing starting at eight weeks of age. Mice were sacrificed and brains were hemisected and processed for either immunohistochemistry, or hippocampus and parietal cortex dissection for Western blotting. MRL/lpr ERαKO mice (n = 21) performed significantly better in WRAM testing than wild-type MRL/lpr mice (n = 25). There was a significant reduction in reference memory errors (P <0.007), working memory errors (P <0.05), and start arm errors (P <0.02) in ERαKO mice. There were significant differences in NOR testing, particularly total exploration time, with ERα deficiency normalizing behavior. No significant differences were seen in markers of tight junction, astrogliosis, or microgliosis in the hippocampus or cortex by Western blot, however, there was a significant reduction in numbers of Iba1+ activated microglia in the hippocampus of ERαKO mice, as evidenced by immunohistochemietry (IHC). ERα deficiency provides significant protection against cognitive deficits in MRL/lpr mice as early as eight weeks of age. Additionally, the significant reduction in Iba1+ activated microglia in the MRL/lpr ERαKO mice was consistent with reduced inflammation, and may represent a biological mechanism for the cognitive improvement observed.
- 1 April 2014
- Published by Elsevier in Brain Research
- Vol. 1557, 164-170
Short-term effects of an endotoxin on substantia nigra dopamine neurons
- 1 April 2014
- Published by Elsevier in Brain Research
- Vol. 1557, 164-170
Short-term effects of an endotoxin on substantia nigra dopamine neurons